Nanostructure-based drug delivery systems for brain targeting

References

• Cardoso FL, Brites D, Brito MA. (2010). Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res Rev, 64:328–363.
   PubMed Web of Science ®Google Scholar
• Iqbal U, Abulrob A, Stanimirovic DB. (2011). Integrated platform for brain imaging and drug delivery across the blood-brain barrier. Methods Mol Biol, 686:465–481.
   PubMedGoogle Scholar
• Begley DJ. (2004). Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther, 104:29–45.
   PubMed Web of Science ®Google Scholar
• Karasova JZ, Pohanka M, Musilek K, Zemek F, Kuca K. (2010). Passive diffusion of acetylcholinesterase oxime reactivators through the blood-brain barrier: Influence of molecular structure. Toxicol in Vitro, 24:1838–1844.
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al. (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther, 303:1029–1037.
   PubMed Web of Science ®Google Scholar
• Sanjuan VM, Alvarez MG, Alvarez IG, Bermejo M. (2010). Drug penetration across the blood–brain barrier: An overview. Nanomedicine, 1:535–562.
   Google Scholar
• Levin VA. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem, 23:682–684.
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. (2003). Brain-targeted drug delivery: Experiences to date. Am J Drug Targ, 1:13– 26.
   Google Scholar
• MacKay JA, Deen DF, Szoka FC Jr . (2005). Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res, 1035:139–153.
   PubMed Web of Science ®Google Scholar
• Campbell M, Ozaki E, Humphries P. (2010). Systemic delivery of therapeutics to neuronal tissues: A barrier modulation approach. Expert Opin Drug Deliv, 7:859–869.
   PubMed Web of Science ®Google Scholar
• Matsuhisa K, Kondoh M, Takahashi A, Yagi K. (2009). Tight junction modulator and drug delivery. Expert Opin Drug Deliv, 6:509–515.
   PubMed Web of Science ®Google Scholar
• Davis SS. (1997). Biomedical applications of nanotechnology–implications for drug targeting and gene therapy. Trends Biotechnol, 15:217–224.
   PubMed Web of Science ®Google Scholar
• Temsamani J, Scherrmann JM, Rees AR, Kaczorek M. (2000). Brain drug delivery technologies: Novel approaches for transporting therapeutics. Pharm Sci Technol Today, 3:155–162.
   PubMedGoogle Scholar
• Misra A, Ganesh S, Shahiwala A, Shah SP. (2003). Drug delivery to the central nervous system: A review. J Pharm Pharm Sci, 6:252–273.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Golden PL, Kang YS, Bickel U. (1997). Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem, 68:1278–1285.
   PubMed Web of Science ®Google Scholar
• Goldmann E. (1913). Vitalfarbung am zentralnervensystem. Abh Konigl Preuss Akad Wiss, 1:1–60.
   Google Scholar
• Abbott NJ, Rönnbäck L, Hansson E. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci, 7:41–53.
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. (2005). The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev, 57:173–185.
   PubMed Web of Science ®Google Scholar
• Reese TS, Karnovsky MJ. (1967). Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol, 34:207–217.
   PubMed Web of Science ®Google Scholar
• Brightman MW, Reese TS. (1969). Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol, 40:648–677.
   PubMed Web of Science ®Google Scholar
• Shen DD, Artru AA, Adkison KK. (2004). Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev, 56:1825–1857.
   PubMed Web of Science ®Google Scholar
• Redzic ZB, Segal MB. (2004). The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv Drug Deliv Rev, 56:1695–1716.
   PubMed Web of Science ®Google Scholar
• Motl S, Zhuang Y, Waters CM, Stewart CF. (2006). Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet, 45:871–903.
   PubMed Web of Science ®Google Scholar
• Schlageter KE, Molnar P, Lapin GD, Groothuis DR. (1999). Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc Res, 58:312–328.
   PubMed Web of Science ®Google Scholar
• Ghersi JE, Leninge BM, Suleman G, Siest G, Minn A. (1994). Localisation of drug-metabolizing enzyme activities to blood–brain interfaces and circumventricular organs. J Neurochem, 62:1089–1096.
   PubMed Web of Science ®Google Scholar
• Lindvall M, Hardebo JE, Owman C. (1980). Barrier mechanisms for neutrotransmitter monoamines in the choroid plexus. Acta Physiol Scand, 108:215–221.
   PubMedGoogle Scholar
• Strazielle N, Ghersi-Egea JF. (1999). Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J Neurosci, 19:6275–6289.
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS. (2008). Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J Cereb Blood Flow Metab, 28:1222–1234.
   PubMed Web of Science ®Google Scholar
• Kalaria RN, Mitchell MJ, Harik SI. (1988). Monoamine oxidases of the human brain and liver. Brain, 111 (Pt 6):1441–1451.
   PubMedGoogle Scholar
• Sura P, Sura R, Enayetallah AE, Grant DF. (2008). Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem, 56:551–559.
   PubMed Web of Science ®Google Scholar
• Ghersi-Egea JF, Strazielle N, Murat A, Jouvet A, Buénerd A, Belin MF. (2006). Brain protection at the blood-cerebrospinal fluid interface involves a glutathione-dependent metabolic barrier mechanism. J Cereb Blood Flow Metab, 26:1165–1175.
   PubMed Web of Science ®Google Scholar
• Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie MW. (2001). Sulfation of thyroid hormone and dopamine during human development: Ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab, 86:2734–2742.
   PubMed Web of Science ®Google Scholar
• Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud PO et al. (2008). ABC transporters, cytochromes P450 and their main transcription factors: Expression at the human blood-brain barrier. J Neurochem, 107:1518–1528.
   PubMed Web of Science ®Google Scholar
• Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA et al. (2009). Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol, 77:897–909.
   PubMed Web of Science ®Google Scholar
• Cornford EM, Hyman S. (1999). Blood-brain barrier permeability to small and large molecules. Adv Drug Deliv Rev, 36:145–163.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (1999). Blood-brain barrier biology and methodology. J Neurovirol, 5:556–569.
   PubMed Web of Science ®Google Scholar
• Tsuji A, Tamai I (1999). Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev, 36:277–290.
   PubMed Web of Science ®Google Scholar
• Segal MB. (2000). The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell Mol Neurobiol, 20:183–196.
   PubMed Web of Science ®Google Scholar
• Spector R. (2000). Drug transport in the mammalian central nervous system: Multiple complex systems. A critical analysis and commentary. Pharmacology, 60:58–73.
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. (2004). Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab, 5:95–108.
   PubMed Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, Bendayan R. (2001). Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev, 53:569–596.
   PubMed Web of Science ®Google Scholar
• Dean M, Annilo T. (2005). Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet, 6:123–142.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455:152–162.
   PubMed Web of Science ®Google Scholar
• Cordon CC, Brien JP, Casals D, Rittman GL, Biedler JL, Melamed MR, Bertino JR.(1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci, 86 (2):695–698.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. (1989). Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem, 37:159–164.
   PubMed Web of Science ®Google Scholar
• Sun H, Dai H, Shaik N, Elmquist WF. (2003). Drug efflux transporters in the CNS. Adv Drug Deliv Rev, 55:83–105.
   PubMed Web of Science ®Google Scholar
• Demeule A, Regina J, Jodoin A, Laplante C, Dagenais F, Berthelet A, Beliveau R. (2002). Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vasc Pharmacol, 38:339–348.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Jonker JW. (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev, 55:3–29.
   PubMed Web of Science ®Google Scholar
• Schinkel AH. (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev, 36:179–194.
   PubMed Web of Science ®Google Scholar
• Sawchuk RJ, Elmquist WF. (2000). Microdialysis in the study of drug transporters in the CNS. Adv Drug Deliv Rev, 45:295–307.
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Löscher W. (2002). P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: Evidence from microdialysis experiments in rats. Neurosci Lett, 327:173–176.
   PubMed Web of Science ®Google Scholar
• Bendayan M. (2002). Morphological and cytochemical aspects of capillary permeability. Microsc Res Tech, 57:327–349.
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Fox K, Lam P, Ling V. (1999). Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem, 259:841–850.
   PubMedGoogle Scholar
• Rajagopal A, Simon SM. (2003). Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell, 14:3389–3399.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. (2000). A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst, 92:1295–1302.
   PubMed Web of Science ®Google Scholar
• Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W et al. (2001). Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia, 42:1501–1506.
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerçeker F, van Vliet EA et al. (2004). Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia, 45:441–451.
   PubMed Web of Science ®Google Scholar
• Török M, Huwyler J, Drewe J, Gutmann H, Fricker G. (1998). Transport of the β-lactam antibiotic benzylpenicillin and the dipeptide glycylsarcosine by brain capillary endothelial cells in vitro. Drug Metab Dispos, 26:1144–1148.
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Löscher W. (2001). P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport, 12:3557–3560.
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Löscher W. (2003). Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther, 306:124–131.
   PubMed Web of Science ®Google Scholar
• Eisenblätter T, Hüwel S, Galla HJ. (2003). Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res, 971:221–231.
   PubMed Web of Science ®Google Scholar
• Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. (2004). Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res, 64:3296–3301.
   PubMed Web of Science ®Google Scholar
• Cooray HC, Blackmore CG, Maskell L, Barrand MA. (2002). Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport, 13:2059–2063.
   PubMed Web of Science ®Google Scholar
• Gao B, Stieger B, Noé B, Fritschy JM, Meier PJ. (1999). Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem, 47:1255–1264.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/ SLC21 family: Phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch, 447:653–665.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. (2004). The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch, 447:465–468.
   PubMed Web of Science ®Google Scholar
• Bronger H, König J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C et al. (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res, 65:11419–11428.
   PubMed Web of Science ®Google Scholar
• Huber RD, Gao B, Sidler Pfändler MA, Zhang-Fu W, Leuthold S, Hagenbuch B et al. (2007). Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol, Cell Physiol, 292:C795–C806.
   PubMed Web of Science ®Google Scholar
• Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH et al. (2008). Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology, 149:6251–6261 [Reference 70].
   PubMed Web of Science ®Google Scholar
• Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH et al. (2008). Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology, 149:6251–6261.
   PubMed Web of Science ®Google Scholar
• Rizwan AN, Burckhardt G. (2007). Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharm Res, 24:450–470.
   PubMed Web of Science ®Google Scholar
• Alebouyeh M, Takeda M, Onozato ML, Tojo A, Noshiro R, Hasannejad H et al. (2003). Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. J Pharmacol Sci, 93:430–436.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res, 24:1227–1251.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Schinkel AH. (2004). Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther, 308:2–9.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. (2006). Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther, 319:879–886.
   PubMed Web of Science ®Google Scholar
• Sweet DH, Miller DS, Pritchard JB. (2001). Ventricular choline transport: A role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem, 276:41611–41619.
   PubMed Web of Science ®Google Scholar
• Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J et al. (2001). Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem, 79:959–969.
   PubMed Web of Science ®Google Scholar
• Inano A, Sai Y, Nikaido H, Hasimoto N, Asano M, Tsuji A et al. (2003). Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Dispos, 24:357–365.
   PubMed Web of Science ®Google Scholar
• Miecz D, Januszewicz E, Czeredys M, Hinton BT, Berezowski V, Cecchelli R et al. (2008). Localization of organic cation/carnitine transporter (OCTN2) in cells forming the blood-brain barrier. J Neurochem, 104:113–123.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Endou H. (2004). The SLC22 drug transporter family. Pflugers Arch, 447:666–676.
   PubMed Web of Science ®Google Scholar
• del Amo EM, Urtti A, Yliperttula M. (2008). Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci, 35:161–174.
   PubMed Web of Science ®Google Scholar
• Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E et al. (2002). Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol, 61:729–737.
   PubMed Web of Science ®Google Scholar
• Verrey F. (2003). System L: Heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Arch, 445:529–533.
   PubMed Web of Science ®Google Scholar
• Su TZ, Feng MR, Weber ML. (2005). Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther, 313:1406–1415.
   PubMed Web of Science ®Google Scholar
• Tsuji A. (2005). Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. Neurorx, 2:54–62.
   PubMedGoogle Scholar
• Pierre K, Pellerin L. (2005). Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J Neurochem, 94:1–14.
   PubMed Web of Science ®Google Scholar
• Morris ME, Felmlee MA. (2008). Overview of the proton-coupled MCT (SLC16A) family of transporters: Characterization, function and role in the transport of the drug of abuse γ-hydroxybutyric acid. AAPS J, 10:311–321.
   PubMed Web of Science ®Google Scholar
• Tsuji A, Saheki A, Tamai I, Terasaki T. (1993). Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther, 267:1085–1090.
   PubMed Web of Science ®Google Scholar
• Bhattacharya I, Boje KM. (2004). GHB (γ-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier. J Pharmacol Exp Ther, 311:92–98.
   PubMed Web of Science ®Google Scholar
• Deguchi Y, Nozawa K, Yamada S, Yokoyama Y, Kimura R. (1997). Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: Possible involvement of the monocarboxylic acid transport system. J Pharmacol Exp Ther, 280:551–560.
   PubMed Web of Science ®Google Scholar
• Fischer W, Praetor K, Metzner L, Neubert RH, Brandsch M. (2008). Transport of valproate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: Mechanism and substrate specificity. Eur J Pharm Biopharm, 70:486–492.
   PubMed Web of Science ®Google Scholar
• Cornford EM, Diep CP, Pardridge WM. (1985). Blood-brain barrier transport of valproic acid. J Neurochem, 44:1541–1550.
   PubMed Web of Science ®Google Scholar
• Adkison KD, Shen DD. (1996). Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther, 276:1189–1200.
   PubMed Web of Science ®Google Scholar
• Kong W, Engel K, Wang J. (2004). Mammalian nucleoside transporters. Curr Drug Metab, 5:63–84.
   PubMed Web of Science ®Google Scholar
• Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, Young JD et al. (2001). Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology, 40:722–731.
   PubMed Web of Science ®Google Scholar
• Nies AT. (2007). The role of membrane transporters in drug delivery to brain tumors. Cancer Lett, 254:11–29.
   PubMed Web of Science ®Google Scholar
• Spector R, Johanson CE. (2007). The origin of deoxynucleosides in brain: Implications for the study of neurogenesis and stem cell therapy. Pharm Res, 24:859–867.
   PubMed Web of Science ®Google Scholar
• Endres CJ, Moss AM, Ke B, Govindarajan R, Choi DS, Messing RO et al. (2009). The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther, 329:387–398.
   PubMed Web of Science ®Google Scholar
• Bickel U. (2005). How to measure drug transport across the blood-brain barrier. Neurorx, 2:15–26.
   PubMedGoogle Scholar
• Pardridge WM. Isolated brain capillaries: And in vitro model of blood-brain barrier research. In: Introduction to the blood-brain barrier: Methodology, biology and pathology (Pardridge WM, ed), pp 49–61. Cambridge, UK: Cambridge University Press, 1998.
   Google Scholar
• Hurst RD, Fritz IB. (1996). Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J Cell Physiol, 167:81–88.
   PubMed Web of Science ®Google Scholar
• Kakee A, Terasaki T, Sugiyama Y. (1996). Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther, 277:1550–1559.
   PubMed Web of Science ®Google Scholar
• Oldendorf WH. (1970). Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res, 24:372–376.
   PubMedGoogle Scholar
• Deguchi Y, Morimoto K. (2001). Application of an in vivo brain microdialysis technique to studies of drug transport across the blood-brain barrier. Curr Drug Metab, 2:411–423.
   PubMed Web of Science ®Google Scholar
• Menacherry S, Hubert W, Justice JB Jr. (1992). In vivo calibration of microdialysis probes for exogenous compounds. Anal Chem, 64:577–583.
   PubMed Web of Science ®Google Scholar
• Janib SM, Moses AS, MacKay JA. (2010). Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev, 62:1052–1063.
   PubMed Web of Science ®Google Scholar
• Yang H. (2010). Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res, 27:1759–1771.
   PubMed Web of Science ®Google Scholar
• Kumari B, Kavimani S, Jaykar B (2010). Development of formulation and in vitro evaluation of sterically stabilized (stealth) liposome containing cytarabine. Journal of Innovative trends in Pharmaceutical Sciences, 1:283–293
   Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet, 42:419–436.
   PubMed Web of Science ®Google Scholar
• Hui HS, Al-Suwayeh A, Chen S, Hsien CC, You FJ. (2011). Pegylated Liposomes Incorporated with Nonionic Surfactants as an Apomorphine Delivery System Targeting the Brain: In Vitro Release and In Vivo Real-time Imaging. Curr Nanosci, 7:191–199.
   Web of Science ®Google Scholar
• Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P; European NanoBioPharmaceutics Research Initiative. (2009). Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol, 87:212–251.
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. (2005). Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int J Pharm, 298:274–292.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. (2002). By-passing of P-glycoprotein using immunoliposomes. J Drug Target, 10:73–79.
   PubMed Web of Science ®Google Scholar
• Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH et al. (2008). Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology, 149:6251–6261.
   PubMed Web of Science ®Google Scholar
• van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. (2011). Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release, 150:30–36.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Yao HJ, Zhang Y, Tian W, Zhang L et al. (2011). Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology, 87:105–114.
   PubMed Web of Science ®Google Scholar
• Angst MS, Drover DR. (2006). Pharmacology of drugs formulated with DepoFoam: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet, 45:1153–1176.
   PubMed Web of Science ®Google Scholar
• Ko YT, Bhattacharya R, Bickel U. (2009). Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release, 133:230–237.
   PubMed Web of Science ®Google Scholar
• Young K, Bhattacharya R. (2009). Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Rel, 133:230–237.
   PubMed Web of Science ®Google Scholar
• Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. (2010). Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci, 99:1745–1761.
   PubMed Web of Science ®Google Scholar
• Artzner F, Zantl R, Rädler JO. (2000). Lipid-DNA and lipid-polyelectrolyte mesophases: Structure and exchange kinetics. Cell Mol Biol (Noisy-Le-Grand), 46:967–978.
   PubMed Web of Science ®Google Scholar
• da Cruz MT, Simões S, de Lima MC. (2004). Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp Neurol, 187:65–75.
   PubMed Web of Science ®Google Scholar
• Molinari A, Colone M, Calcabrini A, Stringaro A, Toccacieli L, Arancia G et al. (2007). Cationic liposomes, loaded with m-THPC, in photodynamic therapy for malignant glioma. Toxicol in Vitro, 21:230–234.
   PubMed Web of Science ®Google Scholar
• Obata Y, Ciofani G, Raffa V, Cuscheiri A, Mensciassi A, Shinji T et al. (2010). Evaluation of cationic liposomes composed of an amino acid based lipid for neuronal transfection. Nanomedicine, 6:70–77.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Cassetti A, Canta A, Galbiati S, Gilardini A, Haas H et al. (2009). Cationic Liposomes Target Sites of Acute Neuroinflammation in Experimental Autoimmune Encephalomyelitis. Mol. Pharmaceutics, 6:1363–1370.
   PubMed Web of Science ®Google Scholar
• Chen H, Tang L, Qin Y, Yin Y, Tang J, Tang W et al. (2010). Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci, 40:94–102.
   PubMed Web of Science ®Google Scholar
• Huang A, Kennel SJ, Huang L. (1981). Immunoliposome labeling: A sensitive and specific method for cell surface labeling. J Immunol Methods, 46:141–151.
   PubMed Web of Science ®Google Scholar
• Huang A, Kennel SJ, Huang L. (1983). Interactions of immunoliposomes with target cells. J Biol Chem, 258:14034–14040.
   PubMed Web of Science ®Google Scholar
• Ho RJ, Huang L. (1985). Interactions of antigen-sensitized liposomes with immobilized antibody: A homogeneous solid-phase immunoliposome assay. J Immunol, 134:4035–4040.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2002). Blood–brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol/source, 513:397–430.
   PubMed Web of Science ®Google Scholar
• Young K, Bhattacharya R. (2009). Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Rel/source, 133:230–237.
   PubMed Web of Science ®Google Scholar
• Chen H, Tang Lei, Qin Y, Yin Y, Tang J, Tang W, Sun X, Zhang Z, Liu J, He Q. (2010). Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Biopharm/source, 40:94–102.
   Web of Science ®Google Scholar
• Cornford EM, Cornford ME. (2002). New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol, 1:306–315.
   PubMed Web of Science ®Google Scholar
• Cornford EM, Hyman S, Cornford ME, Landaw EM, Delgado-Escueta AV. (1998). Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. J Cereb Blood Flow Metab, 18:26–42.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Pardridge WM. (1998). Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem, 70:883–886.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Yang J, Pardridge WM. (1997). Receptor mediated delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther, 282:1541–1546.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xie J, Li S, Wang X, Hou X. (2003). The study on brain targeting of the amphotericin B liposomes. J Drug Target, 11:117–122.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li GL, Wang RZ, Li SF, Wei JJ, Feng M et al. (2010). A comparative study of transfection efficiency between liposomes, immunoliposomes and brain-specific immunoliposomes. J Int Med Res, 38:957–966.
   PubMed Web of Science ®Google Scholar
• Boado RJ. 2007. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res, 24:1772–87.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007). Blood-brain barrier delivery. Drug Discov Today, 12:54–61.
   PubMed Web of Science ®Google Scholar
• Xie YL, Lu W, Jiang XG. (2006). Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav Brain Res, 173:76–84.
   PubMed Web of Science ®Google Scholar
• Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C et al. (2008). Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release, 128:120–127.
   PubMed Web of Science ®Google Scholar
• Du J, Lu WL, Ying X, Liu Y, Du P, Tian W et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm, 6:905–917.
   PubMed Web of Science ®Google Scholar
• Feng B, Tomizawa K, Michiue H, Miyatake S, Han XJ, Fujimura A et al. (2009). Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials, 30:1746–1755.
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. (2007). TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res, 16:351–359.
   PubMed Web of Science ®Google Scholar
• Soni V, Kohli DV, Jain SK. (2008). Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target, 16:73–78.
   PubMed Web of Science ®Google Scholar
• Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T et al. (2008). Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: A modality for boron neutron capture therapy. J Neurooncol, 87:287–294.
   PubMed Web of Science ®Google Scholar
• Tian W, Ying X, Du J, Guo J, Men Y, Zhang Y et al. (2010). Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. Eur J Pharm Sci, 41:232–243.
   PubMed Web of Science ®Google Scholar
• Qin J, Chen D, Hu H, Cui Q, Qiao M, Chen B. (2007). Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. Chem Pharm Bull, 55:1192–1197.
   PubMed Web of Science ®Google Scholar
• Mina T, Hidetaka A, Takahiro F. (2010). Leptin-derived peptide, a targeting ligand for mouse brainderived endothelial cells via macropinocytosis. Biochem Biophys Res Commun, 394:587–592.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Das N. (2006). Mannosylated liposomal flavonoid in combating age-related ischemia-reperfusion induced oxidative damage in rat brain. Mech Ageing Dev, 127:391–397.
   PubMed Web of Science ®Google Scholar
• Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma M. (2005). Nanoemulsions. Curr Opin Colloids Interface Sci, 10:102–110.
   Google Scholar
• Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. (2004). Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm, 275:85–96.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Amiji MM. (2008). Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm, 347:93–101.
   PubMed Web of Science ®Google Scholar
• Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibañez OC et al. (2005). Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: In vitro and in vivo studies. Cancer Chemother Pharmacol, 55:565–576.
   PubMed Web of Science ®Google Scholar
• Edmond J. (2001). Essential polyunsaturated fatty acids and the barrier to the brain: The components of a model for transport. J Mol Neurosci, 16:181–93; discussion 215.
   PubMed Web of Science ®Google Scholar
• Jain A, Chasoo G, Singh SK, Saxena AK, Jain SK. (2011). Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: In vitro characterisation. J Microencapsul, 28:21–28.
   PubMed Web of Science ®Google Scholar
• Kumar M, Pathak K, Misra A. (2009). Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm, 35:387–395.
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. (2008). Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target, 16:806–814.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, Misra A. (2005). Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. J Drug Target, 13:317–324.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. (2006a). Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharmscitech, 7:E8.
   PubMedGoogle Scholar
• Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. (2004). Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm, 275:85–96.
   PubMed Web of Science ®Google Scholar
• Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. (2008). Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord, 22:116–124.
   PubMed Web of Science ®Google Scholar
• Shende AJ, Patil RR, Devarajan PV. (2007). Microemulsion of lamotrigine for nasal delivery. Indian J Pharm Sci, 69:721–722.
   Google Scholar
• Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. (2006b). Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J Pharm Sci, 95:570–580.
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. (2010). Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target, 18:223–234.
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Yeole P, Gaikwad R. (2009). Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. J Pharm Pharmacol, 61:669–675.
   PubMed Web of Science ®Google Scholar
• Yao J, Zhou JP, Ping QN, Lu Y, Chen L. (2008). Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. Int J Pharm, 352:256–262.
   PubMed Web of Science ®Google Scholar
• Madhusudhan B, Rambhau D, Apte SS, Gopinath D. (2007). 1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice. J Drug Target, 15:154–161.
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm, 358:285–291.
   PubMed Web of Science ®Google Scholar
• Horvát S, Fehér A, Wolburg H, Sipos P, Veszelka S, Tóth A et al. (2009). Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm, 72:252–259.
   PubMed Web of Science ®Google Scholar
• Yao J, Zhou JP, Ping QN, Lu Y, Yu L. (2006). Effect of hyaluronic acid chitosan-based microemulsion on the permeability of blood brain barrier in mice. Yao Xue Xue Bao, 41:615–618.
   PubMedGoogle Scholar
• Amiji M, Desai A, Vyas T. (2008). Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsions formulations. J Pharm Sci, 97:2745–2756.
   PubMed Web of Science ®Google Scholar
• Helen B. (2007). A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm, 65:259–69.
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. (2010). Polymer-based nanocapsules for drug delivery. Int J Pharm, 385:113–142.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Benoit JP. (2006). Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release, 112:208–213.
   PubMed Web of Science ®Google Scholar
• Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. (2009). Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today, 14:1067–1074.
   PubMed Web of Science ®Google Scholar
• Battastini AMO. (2009). Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett, 281:53– 63.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release, 127:97–109.
   PubMed Web of Science ®Google Scholar
• Mishra B, Patel BB, Tiwari S. (2010). Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine, 6:9–24.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mehnert W, Lucks JS, Schwarz C, Muhlen AZ, Weyhers H, Freitas C, Ruhl D. (1995). Solid lipid nanopaticles (SLN)—an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 41:62–69.
   Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 59:299–307.
   PubMed Web of Science ®Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59:454–477.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Majumder S, Agrawal H, Majumdar S, Agrawal GP. (2011). Cationized Albumin Conjugated Solid Lipid Nanoparticles as Vectors for Brain Delivery of an Anti-Cancer Drug. Curr Nanosci, 7:71–80.
   Web of Science ®Google Scholar
• Kuo YC, Liang CT. (2011). Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials, 32:3340–3350.
   PubMed Web of Science ®Google Scholar
• Dhawan S, Kapil R, Singh B. (2011). Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol, 63:342–351.
   PubMed Web of Science ®Google Scholar
• Bondi ML, Montana G, Craparo EF, Picone P, Capuano G, Carlo MD, Giammona G. (2009). Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimer’s Disease: Preparation, Characterization and Cytotoxicity Studies. Curr Nanosci, 5:26–32.
   Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. (2006). Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target, 14:632–645.
   PubMed Web of Science ®Google Scholar
• Wang JX, Sun X, Zhang ZR. (2002). Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm, 54:285–290.
   PubMed Web of Science ®Google Scholar
• Alex A, Paul W, Chacko AJ, Sharma CP. (2011). Enhanced delivery of lopinavir to the CNS using Compritol®-based solid lipid nanoparticles. Therap Deliv, 2:25–35.
   PubMedGoogle Scholar
• Bondì ML, Craparo EF, Giammona G, Drago F. (2010). Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution. Nanomedicine (Lond), 5:25–32.
   PubMed Web of Science ®Google Scholar
• Kasongo KW, Jansch M, Müller RH, Walker RB. (2011). Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain. J Liposome Res, 21:245–54.
   PubMed Web of Science ®Google Scholar
• Béduneau A, Hindré F, Clavreul A, Leroux JC, Saulnier P, Benoit JP. (2008). Brain targeting using novel lipid nanovectors. J Control Release, 126:44–49.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. (2007). Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev, 59:491–504.
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, Fundarò A, Vighetto D, Gasco MR. (2002). Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target, 10:327–335.
   PubMed Web of Science ®Google Scholar
• Gref R, Domb A, Quellec P, Blunk T, Mueller RH, Verbavatz JM. (1995). The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev, 16:215–233.
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 70:1–20.
   PubMed Web of Science ®Google Scholar
• Ameller T, Marsaud V, Legrand P, Gref R, Barratt G, Renoir JM. (2003). Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: Physicochemical and opsonization properties. Pharm Res, 20:1063–1070.
   PubMed Web of Science ®Google Scholar
• Kwon GS. (1998). Diblock copolymer nanoparticles for drug delivery. Crit Rev Ther Drug Carrier Syst, 15:481–512.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2004). Drug delivery systems: Entering the mainstream. Science, 303:1818–1822.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA, 93:14164–14169.
   PubMed Web of Science ®Google Scholar
• Lasic DD. (1998). Novel applications of liposomes. Trends Biotechnol, 16:307–321.
   PubMed Web of Science ®Google Scholar
• Khalil NM, Mainardes RM. (2009). Colloidal polymeric nanoparticles and brain drug delivery. Curr Drug Deliv, 6:261–273.
   PubMedGoogle Scholar
• Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ et al. (2003). In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm Res, 20:705–713.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47:65–81.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. (1995). Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res, 674:171–174.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C et al. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10:317–325.
   PubMed Web of Science ®Google Scholar
• Borchard G, Audus KL, Shi F, Kreuter J. (1994). Uptake of surfactant-coated poly (methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm, 110:29–35.
   Web of Science ®Google Scholar
• Alyaudtin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. (2001). Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target, 9:209–221.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. (1997). Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res, 14:325–328.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. (1998). Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J Microencapsul, 15:67–74.
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. (1999). Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res, 16:1564–1569.
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS et al. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer, 109:759–767.
   PubMed Web of Science ®Google Scholar
• Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. (2000). Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm, 49:103–109.
   PubMed Web of Science ®Google Scholar
• Fonseca C, Simões S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release, 83:273–286.
   PubMed Web of Science ®Google Scholar
• Bhadra D, Bhadra S, Jain S, Jain NK. (2003). A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm, 257:111–124.
   PubMed Web of Science ®Google Scholar
• Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. (2004). Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci, 93:1804–1814.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res, 1200:159–168.
   PubMed Web of Science ®Google Scholar
• Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS et al. (2009). Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target, 17:564–574.
   PubMed Web of Science ®Google Scholar
• Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE et al. (2002). Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett, 126:131–141.
   PubMed Web of Science ®Google Scholar
• Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A et al. (2005). Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Control Release, 108:193–214.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 70:75–84.
   PubMed Web of Science ®Google Scholar
• Saiyed ZM, Gandhi NH, Nair MP. (2009). AZT 5′-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J Neurovirol, 15:343–347.
   PubMed Web of Science ®Google Scholar
• Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe MJ, Couvreur P et al. (2002b). Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther, 303:928–936.
   PubMed Web of Science ®Google Scholar
• Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C et al. (2002). Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci, 15:1317–1326.
   PubMed Web of Science ®Google Scholar
• Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, Williams A et al. (2001a). PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J Neurosci Methods, 111:151–155.
   PubMed Web of Science ®Google Scholar
• Peracchia MT, Harnisch S, Pinto-αndary H, Gulik A, Dedieu JC, Desmaële D et al. (1999b). Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials, 20:1269–1275.
   PubMed Web of Science ®Google Scholar
• Calvo P, Gouritin B, Chacun H, Desmaële D, D’Angelo J, Noel JP et al. (2001b). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res, 18:1157–1166.
   PubMed Web of Science ®Google Scholar
• Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. (2008). Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral amyloid angiopathy. Pharm Res, 25:2674–2684.
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm, 70:735–740.
   PubMed Web of Science ®Google Scholar
• Wang S, Jiang T, Ma M, Hu Y, Zhang J. (2010). Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting. Int J Pharm, 386:249–255.
   PubMed Web of Science ®Google Scholar
• Khuller GK, Pandey R. (2006). Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrobial Chem, 57:1146–1152.
   PubMed Web of Science ®Google Scholar
• George J, Hasadsri L, Kreuter J, Hattori H, Iwasaki T. (2009). Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem, 284 (11):6972–81.
   PubMed Web of Science ®Google Scholar
• Rempe R, Cramer S, Hüwel S, Galla HJ. (2011). Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem Biophys Res Commun, 406:64–69.
   PubMed Web of Science ®Google Scholar
• Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. (2010). Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2:35–47.
   PubMed Web of Science ®Google Scholar
• Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV et al. (2007). Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release, 122:1–9.
   PubMed Web of Science ®Google Scholar
• Malhotra M, Prakash S. (2011). Targeted Drug Delivery Across Blood-Brain-Barrier Using Cell Penetrating Peptides Tagged Nanoparticles. Curr Nano, 7:81–93.
   Web of Science ®Google Scholar
• Tahara T, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. (2011). Brain targeting with surface-modified poly (d,l-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm, 77:84–88.
   PubMed Web of Science ®Google Scholar
• Yang Liu Rongqin, Huang, Liang Han Weilun, Ke. (2009). Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials, 30:2009.
   Google Scholar
• Gan CW, Feng SS. (2010). Transferrin-conjugated nanoparticles of poly(lactide)-D-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials, 31:7748–7757.
   PubMed Web of Science ®Google Scholar
• Kwon GS. (2003). Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst, 20:357–403.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Harada A, Nagasaki Y. (2001). Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Deliv Rev, 47:113–131.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Alakhov VY. (2002). Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst, 19:1–72.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2004). Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci, 61:2549–2559.
   PubMed Web of Science ®Google Scholar
• Aliabadi HM, Lavasanifar A. (2006). Polymeric micelles for drug delivery. Expert Opin Drug Deliv, 3:139–162.
   PubMedGoogle Scholar
• Torchilin VP. (2002). PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev, 54:235–252.
   PubMed Web of Science ®Google Scholar
• Kabanov A. (1992). A new class of drug carriers: Micelles of poly (oxyethilene)-poly (oxupropilene) block copolymers as microcontainers for drug targeting from blood in brain. J Contr Release, 22:141–158.
   Web of Science ®Google Scholar
• Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D et al. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer, 90:2085–2091.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y et al. (2004). Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer, 91:1775–1781.
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS et al. (2004). Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res, 10:3708–3716.
   PubMed Web of Science ®Google Scholar
• Matsumura Y. (2006). Micelle carrier system in clinical trial. Nippon Rinsho, 64:316–321.
   PubMedGoogle Scholar
• Armstrong A. (2006). SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study. J Clin Oncol, ASCO annual meeting proceedings, 24:4080.
   Web of Science ®Google Scholar
• Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. (2001). Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br J Cancer, 85:1987–1997.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. (2001). Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther, 299:483–493.
   PubMed Web of Science ®Google Scholar
• Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. (2001). Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides, 22:2329–2343.
   PubMed Web of Science ®Google Scholar
• Alakhov V, Moskaleva E, Batrakova EV, Kabanov AV. (1996). Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem, 7:209–16.
   PubMed Web of Science ®Google Scholar
• Dutta T, Jain NK, McMillan NA, Parekh HS. (2010). Dendrimer nanocarriers as versatile vectors in gene delivery. Nanomedicine, 6:25–34.
   PubMed Web of Science ®Google Scholar
• Pasha S, Gupta K. (2010). Various drug delivery approaches to the central nervous system. Expert Opin Drug Deliv, 7:113–135.
   PubMed Web of Science ®Google Scholar
• Jaturanpinyo M, Harada A, Yuan X, Kataoka K. (2004). Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde. Bioconjug Chem, 15:344–348.
   PubMed Web of Science ®Google Scholar
• Bronich TK, Ouyang M, Kabanov VA, Eisenberg A, Szoka FC Jr , Kabanov AV. (2002). Synthesis of vesicles on polymer template. J Am Chem Soc, 124:11872–11873.
   PubMed Web of Science ®Google Scholar
• Yokosawa M, Sonoda Y, Sugiyama S, Saito R, Yamashita Y, Nishihara M et al. (2010). Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. Tohoku J Exp Med, 221:257–264.
   PubMed Web of Science ®Google Scholar
• Inoue T, Yamashita Y, Nishihara M, Sugiyama S, Sonoda Y, Kumabe T et al. (2009). Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro-Oncology, 11:151–157.
   PubMed Web of Science ®Google Scholar
• Jain R, Nabar S, Dandekar P, Hassan P, Aswal V, Talmon Y et al. (2010). Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine (Lond), 5:575–587.
   PubMed Web of Science ®Google Scholar
• Jain R, Nabar S, Dandekar P, Patravale V. (2010). Micellar nanocarriers: Potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res, 27:655–664.
   PubMed Web of Science ®Google Scholar
• Yáñez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. (2008). Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol, 61:133–144.
   PubMed Web of Science ®Google Scholar
• Patrice H, Dhanikula RS, Hammady T. (2009). On the mechanism and dynamics of uptake and permeation of polyether-copolyester dendrimers across an invitro blood–brain barrier model. J Pharm Sci, 98:3748–60.
   PubMed Web of Science ®Google Scholar
• Capala J, Barth RF, Bendayan M, Lauzon M, Adams DM, Soloway AH et al. (1996). Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem, 7:7–15.
   PubMed Web of Science ®Google Scholar
• Yang W, Barth RF, Adams DM, Soloway AH. (1997). Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res, 57:4333–4339.
   PubMed Web of Science ®Google Scholar
• Yang W, Barth RF, Wu G, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W et al. (2004). Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot, 61:981–985.
   PubMed Web of Science ®Google Scholar
• Gedda L, Olsson P, Pontén J, Carlsson J. (1996). Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. Bioconjug Chem, 7:584–591.
   PubMed Web of Science ®Google Scholar
• Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. (1994). Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem, 5:58–66.
   PubMed Web of Science ®Google Scholar
• Wu G, Barth RF, Yang W, Chatterjee M, Tjarks W, Ciesielski MJ et al. (2004). Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem, 15:185–194.
   PubMed Web of Science ®Google Scholar
• Liu L, Barth RF, Adams DM, Soloway AH, Reisfeld RA. (1995). Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J Hematother, 4:477–483.
   PubMedGoogle Scholar
• Liu L, Barth RF, Adams DM, Soloway AH, Reisfeld RA. (1996). Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Anticancer Res, 16:2581–2587.
   PubMed Web of Science ®Google Scholar
• Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W et al. (2005). Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther, 4:1423–1429.
   PubMed Web of Science ®Google Scholar
• Dhanikula Argaw, A, Bouchard JF, Hildgen P. (2008). Methotrexate loaded polyethercopolyester dendrimers for the treatment of gliomas: Enhanced efficacy and intratumoral transport capability. Mol Pharmaceutics, 5 (1):105–16.
   PubMed Web of Science ®Google Scholar
• Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. (2007). Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Faseb J, 21:1117–1125.
   PubMed Web of Science ®Google Scholar
• Jose LJ, Clemente MI, Weber ND, Sanchez JO, Javier DLM, Gómez RG et al. (2010). Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus. Biodrugs, 24:331–343.
   PubMed Web of Science ®Google Scholar
• Solassol J, Crozet C, Perrier V, Leclaire J, Béranger F, Caminade AM et al. (2004). Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol, 85:1791–1799.
   PubMed Web of Science ®Google Scholar
• Wu G, Yang W, Barth RF, Kawabata S, Swindall M, Bandyopadhyaya AK et al. (2007). Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res, 13:1260–1268.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Batrakova EV, Kabanov AV. (2004). Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem, 15:50–60.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Kohli E, Zeman AD. (2005a). Cross-linked polymeric nanogel formulations of 5′-triphosphates of nucleoside analogues: Role of the cellular membrane in drug release. Mol Pharm, 2:449–461.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV. (2005b). Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Release, 107:143–157.
   PubMed Web of Science ®Google Scholar
• Bronich TK, Bontha S, Shlyakhtenko LS, Bromberg L, Hatton TA, Kabanov AV. (2006). Template-assisted synthesis of nanogels from Pluronic-modified poly(acrylic acid). J Drug Target, 14:357–366.
   PubMed Web of Science ®Google Scholar
• McAllister K, Sazani P, Adam M, Cho MJ, Rubinstein M, Samulski RJ et al. (2002). Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc, 124:15198–15207.
   PubMed Web of Science ®Google Scholar
• Lemieux P, Vinogradov SV, Gebhart CL, Guérin N, Paradis G, Nguyen HK et al. (2000). Block and graft copolymers and NanoGel copolymer networks for DNA delivery into cell. J Drug Target, 8:91–105.
   PubMed Web of Science ®Google Scholar
• Bontha S, Kabanov AV, Bronich TK. (2006). Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. J Control Release, 114:163–174.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Bronich TK, Kabanov AV. (2002). Nanosized cationic hydrogels for drug delivery: Preparation, properties and interactions with cells. Adv Drug Deliv Rev, 54:135–147.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV. (2004). New technologies for drug delivery across the blood brain barrier. Curr Pharm Des, 10:1355–1363.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Poluektova LY, Makarov E, Gerson T, Senanayake MT. (2010). Nano-NRTIs: Efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antivir Chem Chemother, 21:1–14.
   PubMedGoogle Scholar
• Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, Bock A et al. (2004). Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 100:1199–1207.
   PubMed Web of Science ®Google Scholar
• Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS et al. (2000). Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis, 182:274–282.
   PubMed Web of Science ®Google Scholar
• Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M et al. (2004). Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon β gene using cationic liposomes. Hum Gene Ther, 15:77–86.
   PubMed Web of Science ®Google Scholar
• Bhanushali RS, Gatne MM, Gaikwad RV, Bajaj AN, Morde MA. (2009). Nanoemulsion based Intranasal Delivery of Antimigraine Drugs for Nose to Brain Targeting. Indian J Pharm Sci, 71:707–709.
   Web of Science ®Google Scholar
• Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. (2010). Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target, 18:381–388.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Ramasamy M, Suresh B. (2010). Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine, 6:144–152.
   PubMed Web of Science ®Google Scholar
• Soliman GM, Sharma R, Choi AO, Varshney SK, Winnik FM, Kakkar AK et al. (2010). Tailoring the efficacy of nimodipine drug delivery using nanocarriers based on A2B miktoarm star polymers. Biomaterials, 31:8382–8392.
   PubMed Web of Science ®Google Scholar
• Jain N, Akhtar S, Jain GK, Khan ZI, Khar RK, Ahmad FJ. (2011). Antiepileptic Intranasal Amiloride Loaded Mucoadhesive Nanoemulsion: Development and Safety Assessment. Journ Biomed Nanotech, 7:142–143.
   PubMed Web of Science ®Google Scholar